A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction

Abstract
Reteplase (recombinant plasminogen activator), a mutant of alteplase tissue plasminogen activator, has a longer half-life than its parent molecule and produced superior angiographic results in pilot studies of acute myocardial infarction. In this large clinical trial, we compared the efficacy and safety of these two thrombolytic agents.

This publication has 13 references indexed in Scilit: